Esperion Therapeutics Inc (NASDAQ:ESPR) Stock Price Up as ... | espr stock priceespr stock price
(RTTNews.com) - Today's Daily Dose brings you account about the aftereffect of Data and Assurance Monitoring Board' acting assay of ARCA biopharma's GENETIC-AF trial; banal offerings of Dynavax and Esperion; after-effects of Galapagos' idiopathic pulmonary fibrosis study; Heron's advance in appearance III affairs of HTX-011 and Sangamo's auspicious banking results.
["450.08"]
Esperion Therapeutics, Inc. - ESPR - Stock Price Today - Zacks | espr stock priceRead on...
The Data and Assurance Monitoring Board has completed the pre-specified acting assay of ARCA biopharma Inc.'s ( ABIO ) GENETIC-AF trial. The DSMB has asked the Company to abide the balloon with no changes.
The Company expects advertisement top-line after-effects from the GENETIC-AF balloon in the aboriginal division of abutting year.
ABIO bankrupt Wednesday's trading at $1.70, bottomward 8.11%. In after-hours, the banal acquired 8.82% and was at $1.85.
Dynavax Technologies Corp. (DVAX) has offered to advertise 5 actor shares of its accepted banal to the accessible at a amount of $15.00 each.
The Company has accepted the underwriters a 30-day advantage to acquirement at the accessible alms amount up to an accumulated of 750,000 added shares of its accepted banal to awning over-allotments, if any. The gross gain to Dynavax from this alms are accepted to be about $75 million.
The alms is accepted to abutting on or about August 15, 2017, accountable to accepted closing conditions.
The Company's New Biologic Application for Heplisav-B, an beginning hepatitis B vaccine, is beneath FDA review, with a accommodation date set for November 10, 2017.
DVAX bankrupt Wednesday's trading at $17.20, bottomward 7.77%.
["388"]
Esperion Therapeutics, Inc. - ESPR - Stock Price Today - Zacks | espr stock priceEsperion Therapeutics Inc. (ESPR) has offered to advertise 3.10 actor shares of its accepted banal to the accessible at a amount of $49.00 per share.
The underwriters accept a 30-day advantage to acquirement up to an added 465,000 shares of its accepted stock. The gross gain from this alms to Esperion are accepted to be $151.9 million.
The alms is accepted to abutting on or about August 15, 2017, accountable to accepted closing conditions.
Esperion shares affected an best intraday aerial of $57.38 on Aug.8, 2017, afterward absolute top-line after-effects from its appearance II abstraction evaluating the LDL-C blurred ability and assurance of the Bempedoic acid/Ezetimibe aggregate additional Atorvastatin adjoin placebo in patients with hypercholesterolemia.
ESPR bankrupt Wednesday's (Aug.9) trading at $50.54, bottomward 3.05%.
Galapagos NV (GLPG) has appear absolute topline after-effects from its appearance 2a balloon of GLPG1690 in patients with idiopathic pulmonary fibrosis (IPF).
In the trial, dubbed FLORA, over the 12-week period, patients accepting GLPG1690 showed an FVC (forced basic capacity) access of 8 mL, which is of statistical significance, while patients on placebo showed an accepted FVC abridgement of 87 mL (mean from baseline).
The Company affairs to rapidly advance GLPG1690 in a backward date balloon and had already discussions with regulators apropos balloon design.
GLPG bankrupt Wednesday's trading at $62.63, bottomward 1.86%.
["388"]Heron Therapeutics Inc. (HRTX) has accomplished accommodating acceptance in its appearance III affairs of HTX-011, an investigational biologic to anticipate postoperative affliction for the aboriginal 72 hours afterwards surgery.
The affairs includes two cardinal Appearance 3 ability studies in bunionectomy and breach repair, apery a awkward archetypal and a bendable tissue model, respectively.
The primary endpoints of the Appearance 3 ability studies will be the aberration in beggarly breadth beneath the ambit (AUC) of affliction acuteness array through 72 hours compared with placebo.
The appearance III affairs is accepted to be completed in the aboriginal bisected of 2018.
HRTX bankrupt Wednesday's trading at $15.30, bottomward 3.47%. In after-hours, the banal was up 4.87% to $16.04.
Organovo Holdings Inc. (ONVO) has appear better-than accepted acquirement for budgetary aboriginal division of 2018 while its annual accident has appear in band with analysts' estimate.
In the three months concluded June 30, 2017, absolute acquirement rose to $990 thousand from $891 thousand in the commensurable aeon of budgetary 2017. Analysts polled by Thomson Reuters were assured acquirement of $940 thousand.
Net accident was $10.1 actor or $0.10 per allotment for the budgetary aboriginal division of 2018, in band with analysts' estimate. This compared with a net accident of $8.8 actor or $0.09 per allotment for the budgetary aboriginal division of 2017.
Looking ahead, the Company expects absolute acquirement of amid $6.0 actor and $8.5 actor for fiscal-year 2018. Budgetary 2017 absolute acquirement was $4.2 million. Wall Street analysts' accord acquirement appraisal for budgetary 2018 is $7 million.
["597.52"]
ESPR - Esperion Therapeutics Inc Stock quote - CNNMoney.com | espr stock priceONVO bankrupt Wednesday's trading at $2.08, bottomward 0.95%. In after-hours, the banal was up 8.17% to $2.25.
Sangamo Therapeutics Inc. (SGMO) has appear a narrower accident and college revenue.for the additional division 2017.
For the additional division concluded June 30, 2017, Sangamo's circumscribed net accident is $12.5 actor or $0.17 per allotment on acquirement of $8.3 million. This compared with a net accident of $26.6 actor or $0.38 per allotment and acquirement of $3.7 actor for the aforementioned aeon in 2016.
Analysts polled by Thomson Reuters accepted the Company to acquire a accident of $0.19 per allotment and acquirement of $5.98 million.
As of June 30, 2017, the Company had banknote of $266.5 million.
SGMO bankrupt Wednesday's trading at $8.45, bottomward 2.87%. In after-hours, the banal was up 5.33% to $8.90.
For comments and feedback: acquaintance editorial@rttnews.com
http://www.rttnews.com
["557.75"]
Why Esperion Therapeutics (ESPR) Stock is Climbing Today - TheStreet | espr stock price["388"]
["388"]
Esperion Therapeutics, Inc. (ESPR) PE Ratio - NASDAQ.com | espr stock price["557.75"]
Esperion (ESPR) Stock Hits Another 52-Week High Today - TheStreet | espr stock price["388"]
["388"]
ESPR biopharma stock chatter | espr stock price["523.8"]
Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 8.6% - March 9 ... | espr stock price["679"]
Esperion Therapeutics, Inc. | $ESPR Stock | Shares Crash Down On ... | espr stock price